Trials / No Longer Available
No Longer AvailableNCT04578444
An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer
Expanded Access Use of Zanidatamab for the Treatment of HER2-Positive Advanced Solid Tumor
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Jazz Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an intermediate-size Expanded Access Protocol (EAP) for use of zanidatamab (ZW25) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced biliary tract cancer (BTC) who are not eligible for other zanidatamab clinical trials, and who in the opinion of the treating oncologist, would potentially benefit from treatment with zanidatamab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanidatamab | Administered intravenously |
Timeline
- First posted
- 2020-10-08
- Last updated
- 2025-05-25
Locations
17 sites across 5 countries: United States, France, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT04578444. Inclusion in this directory is not an endorsement.